Chronic Kidney Disease Stage 3B

2

Review clinical trials related to Chronic Kidney Disease Stage 3B. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD)

The KDOQI 2020 - Clinical practice guideline for nutrition in chronic kidney disease (CKD) -recommends protein restriction to reduce the risk of end-stage renal disease/death and improve quality of life, a low protein diet providing 0.55-0.60g dietary protein/ kg body weight/day is recommended. FLAVIS® is a product line of hypoprotein foods specially developed for the treatment of CKD.The use of low-protein foods may facilitate the achievement of nutritional goals in terms of protein intake and help patients to follow a low-protein diet.

Participants needed: 244
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Dr. Schär AG / SPAUpdated: Jan 29, 2025Locations: 21
Eligibility criteria

CKD patient stage 3a-5 (<60 ml/min/1.73 m² estimated by CKD-EPI formula) and not... [+7]

Patient for whom dialysis or transplantation is planned/expected within the next... [+12]

Status: Not yet recruiting

Fluorescein Angiography in Patients With Diabetes and Chronic Kidney Disease

Our study hypothesizes that fluorescein exposure in diabetic patients with advanced chronic kidney disease results in deterioration of kidney function. It will therefore aim to evaluate the incidence of acute kidney injury induced by fluorescein in diabetic patients with CKD. The objective is to determine the incidence, severity and risk factors associated with this deterioration to improve the care of this specific population.

Participants needed: 35
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Saint-Joseph UniversityUpdated: Jan 7, 2025Locations: 1
Eligibility criteria

>18 years old with type 2 or type 1 diabetes and chronic kidney disease stage 3b...

Patients who do not give their consent [+4]